stella
beta
A Post-Marketing Surveillance Study to Assess the Safety of Fedratinib in Korean Patients With Myelofibrosis — Stella
Home
/
Primary Myelofibrosis
/
A Post-Marketing Surveillance Study to Assess the Safety of Fedratinib in Korean Patients With Myelofibrosis
View on ClinicalTrials.gov
Recruiting
Back to Primary Myelofibrosis trials
A Post-Marketing Surveillance Study to Assess the Safety of Fedratinib in Korean Patients With Myelofibrosis
Trial locations
(3 sites)
South Korea
Bristol-Myers Squibb YH, Seoul
Local Institution - 0001, Seoul
Novotech Laboratory Korea Co., Ltd., Seoul